Penetration of DGAVP (Org 5667) across the blood-brain barrier in human subjects
To assess the penetration of desglycinamide-arginine-vasopressin (DGAVP, Org 5667) to the central nervous system, levels of DGAVP were measured in the lumbar CSF after peripheral administration. DGAVP (2 mg) was administered intranasally to 37 patients and CSF samples were collected from these patie...
Gespeichert in:
| Veröffentlicht in: | Peptides (New York, N.Y. : 1980) N.Y. : 1980), 1987-03, Vol.8 (2), p.261-265 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 265 |
|---|---|
| container_issue | 2 |
| container_start_page | 261 |
| container_title | Peptides (New York, N.Y. : 1980) |
| container_volume | 8 |
| creator | Riekkinen, Paavo Legros, Jean-Jacques Sennef, Cor Jolkkonen, Jukka Smitz, Simon Soininen, Hilkka |
| description | To assess the penetration of desglycinamide-arginine-vasopressin (DGAVP, Org 5667) to the central nervous system, levels of DGAVP were measured in the lumbar CSF after peripheral administration. DGAVP (2 mg) was administered intranasally to 37 patients and CSF samples were collected from these patients 5 to 240 minutes later. Detectable levels of DGAVP in CSF could be found 5 minutes after administration, but levels declined rapidly during the next 90 minutes. The DGAVP levels in CSF correlated with plasma levels of DGAVP (r=0.586,
p |
| doi_str_mv | 10.1016/0196-9781(87)90101-X |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77562570</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>019697818790101X</els_id><sourcerecordid>77562570</sourcerecordid><originalsourceid>FETCH-LOGICAL-c417t-c98ce3af5467b041dd9795aa9ded259a376c7c10d8fcf89c45432e2d092b6ed3</originalsourceid><addsrcrecordid>eNqFkEtLxDAQgIMo6_r4Bwo5iOihmrR5XoRlfYLgHhbxFtJkqpFuq0kr-O_tusse9TTDzDfDzIfQESUXlFBxSagWmZaKnil5rslQy1620JgqWWScCr2NxhtkF-2l9E4IYUyrERoVXKmCiTGazaCBLtoutA1uK3x9N3me4bOn-Iq5EPIcWxfblHD3Bris29ZnZbShwaWNMUDEQ_rWL2yDU1--g-vSAdqpbJ3gcB330fz2Zj69zx6f7h6mk8fMMSq7zGnloLAVZ0KWhFHvtdTcWu3B51zbQgonHSVeVa5S2jHOihxyT3ReCvDFPjpdrf2I7WcPqTOLkBzUtW2g7ZORkoucS_IvSJnkssiXIFuBvw9HqMxHDAsbvw0lZincLG2apU2jpPkVbl6GseP1_r5cgN8MrQ0P_ZN13yZn6yraxoW0wSQTIs_VgF2tMBicfQ1mTXIBGgc-xEGr8W34-44fyu6apQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>14757320</pqid></control><display><type>article</type><title>Penetration of DGAVP (Org 5667) across the blood-brain barrier in human subjects</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Riekkinen, Paavo ; Legros, Jean-Jacques ; Sennef, Cor ; Jolkkonen, Jukka ; Smitz, Simon ; Soininen, Hilkka</creator><creatorcontrib>Riekkinen, Paavo ; Legros, Jean-Jacques ; Sennef, Cor ; Jolkkonen, Jukka ; Smitz, Simon ; Soininen, Hilkka</creatorcontrib><description>To assess the penetration of desglycinamide-arginine-vasopressin (DGAVP, Org 5667) to the central nervous system, levels of DGAVP were measured in the lumbar CSF after peripheral administration. DGAVP (2 mg) was administered intranasally to 37 patients and CSF samples were collected from these patients 5 to 240 minutes later. Detectable levels of DGAVP in CSF could be found 5 minutes after administration, but levels declined rapidly during the next 90 minutes. The DGAVP levels in CSF correlated with plasma levels of DGAVP (r=0.586,
p<0.001). According to these results, DGAVP may gain access to the central nervous system and may induce central effects.</description><identifier>ISSN: 0196-9781</identifier><identifier>EISSN: 1873-5169</identifier><identifier>DOI: 10.1016/0196-9781(87)90101-X</identifier><identifier>PMID: 3588346</identifier><identifier>CODEN: PPTDD5</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Administration, Intranasal ; Adult ; Aged ; Arginine Vasopressin - administration & dosage ; Arginine Vasopressin - analogs & derivatives ; Arginine Vasopressin - cerebrospinal fluid ; Arginine Vasopressin - metabolism ; Biological and medical sciences ; Blood-Brain Barrier ; Cerebrospinal fluid ; Female ; Human subjects ; Humans ; Kinetics ; Male ; Medical sciences ; Middle Aged ; Miscellaneous ; Nervous System Diseases - cerebrospinal fluid ; Nervous System Diseases - metabolism ; Neuropharmacology ; Pharmacology. Drug treatments ; Vasopressin analogue</subject><ispartof>Peptides (New York, N.Y. : 1980), 1987-03, Vol.8 (2), p.261-265</ispartof><rights>1987</rights><rights>1988 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c417t-c98ce3af5467b041dd9795aa9ded259a376c7c10d8fcf89c45432e2d092b6ed3</citedby><cites>FETCH-LOGICAL-c417t-c98ce3af5467b041dd9795aa9ded259a376c7c10d8fcf89c45432e2d092b6ed3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/019697818790101X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=7466228$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3588346$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Riekkinen, Paavo</creatorcontrib><creatorcontrib>Legros, Jean-Jacques</creatorcontrib><creatorcontrib>Sennef, Cor</creatorcontrib><creatorcontrib>Jolkkonen, Jukka</creatorcontrib><creatorcontrib>Smitz, Simon</creatorcontrib><creatorcontrib>Soininen, Hilkka</creatorcontrib><title>Penetration of DGAVP (Org 5667) across the blood-brain barrier in human subjects</title><title>Peptides (New York, N.Y. : 1980)</title><addtitle>Peptides</addtitle><description>To assess the penetration of desglycinamide-arginine-vasopressin (DGAVP, Org 5667) to the central nervous system, levels of DGAVP were measured in the lumbar CSF after peripheral administration. DGAVP (2 mg) was administered intranasally to 37 patients and CSF samples were collected from these patients 5 to 240 minutes later. Detectable levels of DGAVP in CSF could be found 5 minutes after administration, but levels declined rapidly during the next 90 minutes. The DGAVP levels in CSF correlated with plasma levels of DGAVP (r=0.586,
p<0.001). According to these results, DGAVP may gain access to the central nervous system and may induce central effects.</description><subject>Administration, Intranasal</subject><subject>Adult</subject><subject>Aged</subject><subject>Arginine Vasopressin - administration & dosage</subject><subject>Arginine Vasopressin - analogs & derivatives</subject><subject>Arginine Vasopressin - cerebrospinal fluid</subject><subject>Arginine Vasopressin - metabolism</subject><subject>Biological and medical sciences</subject><subject>Blood-Brain Barrier</subject><subject>Cerebrospinal fluid</subject><subject>Female</subject><subject>Human subjects</subject><subject>Humans</subject><subject>Kinetics</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Miscellaneous</subject><subject>Nervous System Diseases - cerebrospinal fluid</subject><subject>Nervous System Diseases - metabolism</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Vasopressin analogue</subject><issn>0196-9781</issn><issn>1873-5169</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1987</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEtLxDAQgIMo6_r4Bwo5iOihmrR5XoRlfYLgHhbxFtJkqpFuq0kr-O_tusse9TTDzDfDzIfQESUXlFBxSagWmZaKnil5rslQy1620JgqWWScCr2NxhtkF-2l9E4IYUyrERoVXKmCiTGazaCBLtoutA1uK3x9N3me4bOn-Iq5EPIcWxfblHD3Bris29ZnZbShwaWNMUDEQ_rWL2yDU1--g-vSAdqpbJ3gcB330fz2Zj69zx6f7h6mk8fMMSq7zGnloLAVZ0KWhFHvtdTcWu3B51zbQgonHSVeVa5S2jHOihxyT3ReCvDFPjpdrf2I7WcPqTOLkBzUtW2g7ZORkoucS_IvSJnkssiXIFuBvw9HqMxHDAsbvw0lZincLG2apU2jpPkVbl6GseP1_r5cgN8MrQ0P_ZN13yZn6yraxoW0wSQTIs_VgF2tMBicfQ1mTXIBGgc-xEGr8W34-44fyu6apQ</recordid><startdate>19870301</startdate><enddate>19870301</enddate><creator>Riekkinen, Paavo</creator><creator>Legros, Jean-Jacques</creator><creator>Sennef, Cor</creator><creator>Jolkkonen, Jukka</creator><creator>Smitz, Simon</creator><creator>Soininen, Hilkka</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>19870301</creationdate><title>Penetration of DGAVP (Org 5667) across the blood-brain barrier in human subjects</title><author>Riekkinen, Paavo ; Legros, Jean-Jacques ; Sennef, Cor ; Jolkkonen, Jukka ; Smitz, Simon ; Soininen, Hilkka</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c417t-c98ce3af5467b041dd9795aa9ded259a376c7c10d8fcf89c45432e2d092b6ed3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1987</creationdate><topic>Administration, Intranasal</topic><topic>Adult</topic><topic>Aged</topic><topic>Arginine Vasopressin - administration & dosage</topic><topic>Arginine Vasopressin - analogs & derivatives</topic><topic>Arginine Vasopressin - cerebrospinal fluid</topic><topic>Arginine Vasopressin - metabolism</topic><topic>Biological and medical sciences</topic><topic>Blood-Brain Barrier</topic><topic>Cerebrospinal fluid</topic><topic>Female</topic><topic>Human subjects</topic><topic>Humans</topic><topic>Kinetics</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Miscellaneous</topic><topic>Nervous System Diseases - cerebrospinal fluid</topic><topic>Nervous System Diseases - metabolism</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Vasopressin analogue</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Riekkinen, Paavo</creatorcontrib><creatorcontrib>Legros, Jean-Jacques</creatorcontrib><creatorcontrib>Sennef, Cor</creatorcontrib><creatorcontrib>Jolkkonen, Jukka</creatorcontrib><creatorcontrib>Smitz, Simon</creatorcontrib><creatorcontrib>Soininen, Hilkka</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Peptides (New York, N.Y. : 1980)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Riekkinen, Paavo</au><au>Legros, Jean-Jacques</au><au>Sennef, Cor</au><au>Jolkkonen, Jukka</au><au>Smitz, Simon</au><au>Soininen, Hilkka</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Penetration of DGAVP (Org 5667) across the blood-brain barrier in human subjects</atitle><jtitle>Peptides (New York, N.Y. : 1980)</jtitle><addtitle>Peptides</addtitle><date>1987-03-01</date><risdate>1987</risdate><volume>8</volume><issue>2</issue><spage>261</spage><epage>265</epage><pages>261-265</pages><issn>0196-9781</issn><eissn>1873-5169</eissn><coden>PPTDD5</coden><abstract>To assess the penetration of desglycinamide-arginine-vasopressin (DGAVP, Org 5667) to the central nervous system, levels of DGAVP were measured in the lumbar CSF after peripheral administration. DGAVP (2 mg) was administered intranasally to 37 patients and CSF samples were collected from these patients 5 to 240 minutes later. Detectable levels of DGAVP in CSF could be found 5 minutes after administration, but levels declined rapidly during the next 90 minutes. The DGAVP levels in CSF correlated with plasma levels of DGAVP (r=0.586,
p<0.001). According to these results, DGAVP may gain access to the central nervous system and may induce central effects.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>3588346</pmid><doi>10.1016/0196-9781(87)90101-X</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0196-9781 |
| ispartof | Peptides (New York, N.Y. : 1980), 1987-03, Vol.8 (2), p.261-265 |
| issn | 0196-9781 1873-5169 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_77562570 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Administration, Intranasal Adult Aged Arginine Vasopressin - administration & dosage Arginine Vasopressin - analogs & derivatives Arginine Vasopressin - cerebrospinal fluid Arginine Vasopressin - metabolism Biological and medical sciences Blood-Brain Barrier Cerebrospinal fluid Female Human subjects Humans Kinetics Male Medical sciences Middle Aged Miscellaneous Nervous System Diseases - cerebrospinal fluid Nervous System Diseases - metabolism Neuropharmacology Pharmacology. Drug treatments Vasopressin analogue |
| title | Penetration of DGAVP (Org 5667) across the blood-brain barrier in human subjects |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T23%3A49%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Penetration%20of%20DGAVP%20(Org%205667)%20across%20the%20blood-brain%20barrier%20in%20human%20subjects&rft.jtitle=Peptides%20(New%20York,%20N.Y.%20:%201980)&rft.au=Riekkinen,%20Paavo&rft.date=1987-03-01&rft.volume=8&rft.issue=2&rft.spage=261&rft.epage=265&rft.pages=261-265&rft.issn=0196-9781&rft.eissn=1873-5169&rft.coden=PPTDD5&rft_id=info:doi/10.1016/0196-9781(87)90101-X&rft_dat=%3Cproquest_cross%3E77562570%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=14757320&rft_id=info:pmid/3588346&rft_els_id=019697818790101X&rfr_iscdi=true |